Endo settled off-label charges for $192 million, resolving civil "whistleblower" suits filed by two sales reps and a physician.
The FDA commissioner said the agency is doing its job, not picking a fight, when it inspects drug-making facilities, and that India must take an active role for a harmonious supply chain.
The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.
Gaming does not trivialize the patient's experience of a chronic disease
Success cures fear, and success is born out of focus and hard work
FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals
Missing documents allegedly kept a review of Tamiflu from conclusively examining the drug's efficacy. Are reviews marred by publication and reporting biases? What can be done to make assessments more robust?